This episode builds a real framework for chronic pain by connecting two worlds that rarely get stitched together: (1) a mechanistic review arguing that mitochondrial dysfunction drives pain chronification, and (2) a systematic review of randomized clinical trials on photobiomodulation (PBM) — red/near-infrared light therapy — for chronic pain. Dr. Mike Belkowski explains why chronic pain is a bioenergetic + redox + immune signaling loop (ATP instability, mitochondrial ROS, calcium overload, neuroinflammation, and quality-control failure), then maps where PBM appears to help most in humans (especially fibromyalgia and peripheral neuropathies) while being honest about the biggest limitation: protocol variability. The punchline is practical and responsible: PBM isn’t a stand-alone magic fix — it’s best viewed as a mitochondria-targeted module inside a larger systems strategy.

(Educational content only, not medical advice.)

Articles Discussed in Episode:

Photobiomodulation in chronic pain: a systematic review of randomized clinical trials

Key Quotes From Dr. Mike:

“Chronic pain is a bioenergetic problem…”

“What makes chronic pain chronic is that the pain system changes.”

“Pain transmission is expensive. Every action potential costs energy.”

“PBM… may be one of the cleanest real-world tests of a mitochondria-first pain model.”

“PBM should be seen as a module inside a larger system strategy, not a magic stand-alone fix.”

Key Points

Chronic pain persists because the pain system changes: sensitization + amplification (“gain knob” turned up).
Pain transmission is energy expensive; mitochondrial strain makes neurons hyperexcitable.
The chronification loop: ATP instability → ROS amplification → calcium dysregulation/MPTP risk → mtDAMPs → NLRP3 + cytokines → glial amplification → more excitability → more mitochondrial damage.
Mitochondrial quality control fails in chronic pain: mitophagy ↓, biogenesis ↓ (PGC-1α/NRF1/TFAM), dynamics skew (DRP1), transport disrupted.
PBM is a strong real-world test because it’s fundamentally a mitochondria-influencing signal.
RCT review (2015–2025) finds PBM often reduces pain, most consistently in fibromyalgia and peripheral neuropathies, with low adverse events.
The limiting factor is heterogeneity: wavelengths, dose, frequency, devices, outcome measures, and follow-up windows vary widely.
Responsible take: PBM is best viewed as a module inside a larger system strategy, not a stand-alone fix.
Timing matters: pain chronification is a trajectory; earlier intervention may prevent “lock-in,” later intervention typically requires stacked strategies.

Episode timeline

0:41–1:33 — Mission: connect mechanistic model to RCT evidence; what each source is
1:48–2:56 — Unified pain-energy model + disclaimer
2:56–3:40 — Definition: pain persists because the system changes; “gain knob” up
3:45–6:07 — Mechanistic engine: energy crisis → ROS → calcium/MPTP → mtDAMPs/NLRP3 → QC failure → lock-in
6:14–6:54 — Clinical trials review summary: PBM often helps (fibromyalgia/neuropathy), but variability limits standardization
7:11–8:53 — Step 1: energy failure; “unstable bioenergetics”
8:53–10:18 — Step 2: mitochondrial ROS as a signaling amplifier
10:18–12:12 — Step 3: calcium overload + permeability transition
12:12–14:07 — Step 4: mtDAMPs → neuroinflammation → central sensitization loop
14:11–16:36 — Step 5: quality control failure + cell-type specificity (neurons, glia, Schwann cells)
16:36–19:06 — Pain types where mitochondrial signatures show up; therapy implications (mitoQ/mitoTEMPO, melatonin, NAD+ precursors, SS-31, etc.)
19:12–21:54 — PBM mechanisms + what RCTs found + heterogeneity
21:54–26:15 — Compare/contrast: where sources agree, where they differ, why they complement
26:22–27:18 — Integrated conclusion: mito-first model predicts PBM works best in sensitization/metabolic stress phenotypes
27:31–30:40 — Practice implications in layers (remove stressors → restore QC → PBM module → precision targeting)
30:40–31:08 — “Not in your head” clarification: it’s physiology
31:16–33:42 — Responsible PBM conclusion: promising, safe profile, needs standardization/long follow-up
34:16–34:57 — Time matters: acute → chronic trajectory
34:59–37:38 — BioLight framing + 3 conclusions (engine > symptom suppression; PBM isn’t woo; future = precision)

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

Stay up-to-date on social media:

Dr. Mike Belkowski:

BioLight: